Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation  Apostolos Apostolidis, Axel Haferkamp,

Slides:



Advertisements
Similar presentations
Botulinum toxin for neuropathic bladder Amir Hooshang Vahedi MD - Physiatrist.
Advertisements

Case Studies in Neurological Rehabilitation Botulinum toxin for neuropathic bladder Alireza Ashraf, M.D. Professor of Physical Medicine & Rehabilitation.
Function of Ureter and Urinary Bladder
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Pascal Rischmann  European Urology Supplements 
Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection 
or multiple system atrophy (MSA)
Neurons.
Micturition Domina Petric, MD.
Robotic Cystectomy Versus Open Cystectomy: Are We There Yet?
Volume 50, Issue 5, Pages (November 2006)
Volume 62, Issue 6, Pages (December 2012)
Bladder Cancer: Management and Future Directions
Volume 57, Issue 6, Pages (June 2010)
Volume 45, Issue 4, Pages (April 2004)
Volume 57, Issue 5, Pages (May 2010)
Volume 46, Issue 2, Pages (August 2004)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Bladder Cancer: A Major Public Health Issue
What is New in Bladder Cancer Diagnosis and Management?
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Mechanisms of inflammatory pain
Long-Term Management of Overactive Bladder with Antimuscarinic Agents
Christian A. von Hehn, Ralf Baron, Clifford J. Woolf  Neuron 
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Spread of OnabotulinumtoxinA After Bladder Injection
Counselling the Prostate Cancer Patient
Volume 69, Issue 2, Pages (February 2016)
Functional Bladder Problems
Volume 61, Issue 5, Pages (May 2012)
Volume 53, Issue 2, Pages (February 2008)
Volume 53, Issue 6, Pages (June 2008)
Volume 57, Issue 5, Pages (May 2010)
Richard C. Harkaway  European Urology Supplements 
The Economic Costs of Overactive Bladder in Germany
Treatment of postherpetic neuralgia: a review of therapeutic options
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Philip Toozs-Hobson, Pallavi Latthe  European Urology Supplements 
The Importance of Testosterone Control in Prostate Cancer
Optimal Testosterone Control and Eligard®
Neal Shore  European Urology Supplements 
Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report1  Dennis D Dykstra, MD,
Christian Stief  European Urology Supplements 
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
William D Steers  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Volume 55, Issue 3, Pages (March 2009)
Botulinum Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity Combined With Low-Compliance Bladder in Patients With Spinal Cord Lesions 
Martin Michel, Jean de la Rosette  European Urology Supplements 
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
Richard Berges  European Urology Supplements 
Nat. Rev. Urol. doi: /nrurol
Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies  David A. Ginsberg, MD, Lynne Kolton.
Improving Flexibility and Quality of Life for Your Patients: A Must?
Profile of Silodosin European Urology Supplements
Volume 52, Issue 6, Pages (December 2007)
The Neuro-Urological Connection
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity  Apostolos Apostolidis, Prokar Dasgupta,
The Impact of Premature Ejaculation on Partners and Relationships
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Diagnosis and Management of Cryptorchidism
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Jan Roigas  European Urology Supplements 
Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?  B. Tombal  European Urology.
Presentation transcript:

Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation  Apostolos Apostolidis, Axel Haferkamp, K. Roger Aoki  European Urology Supplements  Volume 5, Issue 11, Pages 670-678 (July 2006) DOI: 10.1016/j.eursup.2006.05.006 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Bladder signalling in health. In healthy patients, sensation of bladder fullness is conveyed by the mechanosensitive Aδ afferent axons, whereas the primarily nociceptive C-fibres do not normally respond to mechanical distension and remain quiescent. Stimuli associated with the sensation of bladder fullness then ascend via the spinal cord to an integrative brain centre, the periaqueductal grey (PAG), and are relayed to the pontine micturition centre (PMC), which promotes micturition via excitatory parasympathetic outflow to the bladder. European Urology Supplements 2006 5, 670-678DOI: (10.1016/j.eursup.2006.05.006) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Bladder signalling in neurogenic detrusor overactivity. Following the disruption of the spinobulbospinal pathways, as in conditions associated with spinal neurogenic detrusor overactivity, capsaicin-sensitive C-fibre afferents in the suburothelium undergo hypertrophy and display increased excitability, consequently becoming sensitive to mechanical stimuli. Such changes lead to increased afferent firing to the spinal cord during bladder distension, increased parasympathetic input to the bladder and, thus, detrusor overactivity. European Urology Supplements 2006 5, 670-678DOI: (10.1016/j.eursup.2006.05.006) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Intradetrusor BoNT/A injections produced progressive decrease and eventual ‘normalisation’ of mean P2X3 (a) and TRPV1 (b) immunoreactivity in suburothelial nerve fibres at 16 weeks after successful treatment in a group of patients suffering from intractable NDO or IDO. European Urology Supplements 2006 5, 670-678DOI: (10.1016/j.eursup.2006.05.006) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 4 Proposed ‘cascade’ mechanism of action of intravesically injected BoNT/A via multiple inhibition of the vesicular release of neurotransmitters and neuropeptides by the urothelium and suburothelial nerves and reduction of the axonal expression of SNARE-complex dependent proteins that are thought to be involved in bladder mechanosensation (reproduced with permission from Eur Urol 2006;49:644–650). European Urology Supplements 2006 5, 670-678DOI: (10.1016/j.eursup.2006.05.006) Copyright © 2006 European Association of Urology Terms and Conditions